Trial Profile
A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Mosunetuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary) ; Vincristine (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 12 Dec 2023 Results assessing Molecular Determinants of Response to Mosunetuzumab Plus (R-CHOP) NCT01287741 and M-CHOP in NCT03677141 , in Patients with Diffuse Large B Cell Lymphoma , presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 08 Nov 2023 Status changed from active, no longer recruiting to completed.
- 29 Sep 2023 Planned End Date changed from 30 Nov 2023 to 12 Oct 2023.